

## Freedom of Information Act Request

I am writing to request information under the Freedom of Information Act 2000.

I am currently a first year PhD student at Queen's University Belfast, studying clinical trial participation rates for blood cancer throughout the UK.

Under the Freedom of Information Act of 2000, I would like to request the following information for your healthcare trust during the period 1st Jan 2015 to 31st December 2025:

1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:
  - Lymphomas (C81-86)
  - Malignant immunoproliferative diseases (C88)
  - Multiple myeloma and malignant plasma cell neoplasms (C90)
  - Leukaemia (C91-C95)
  - Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)

The Trust is unable to comply with this request in full as responding would exceed the cost limit set out in Section 12 of the Freedom of Information Act 2000.

The information requested spans an 11-year period and requires the identification and validation of diagnosis data across multiple cancer subtypes using ICD-10 codes. This information is not held in a single, readily reportable format and would require:

- Manual interrogation of historical clinical and coding systems
- Validation of diagnosis dates and coding accuracy across different time periods
- Cross-checking to avoid duplication and ensure data quality
- Input from multiple teams, including clinical coding and information services

Undertaking this work would exceed the statutory cost limit of £450 (18 hours) as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004.

### Advice and assistance (Section 16)

In accordance with Section 16 of the Act, the Trust can advise that your request may be refined so that it may be answered within the cost limit. For example, you may wish to consider narrowing your request to one or more of the following:

- A shorter time period (e.g. the most recent 1–3 years)
- A request limited to one blood cancer subtype only
- A request for aggregate totals only, without annual breakdowns
- Information for a single calendar or financial year

If you wish to submit a refined request, the Trust will be happy to reconsider it.

2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting.

There have been 20 trials open in this speciality between 2015 and 2025

3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year.

Of those 20 trials, 7 studies recruited patients between 2015 and 2025

AML 19

- 2017- 5
- 2018-8

Flair

- 2015 – #
- 2016-#
- 2018- #
- 2021 – #
- 2024- #
- 2025-#

National Cohort study for late effects Hodgkins

- 2018 – 19

CANC 3619

- 2021 – #

EPIC

- 2023 – 6
- 2024- #
- 2025 – #

PROPEL

- 2023 – #
- 2024 – #
- 2025 -#

RADAR

- 2024 – 5
- 2025 – #

In line with the Trust's disclosure control policy, numbers fewer than five have been replaced with “#”.

This is to reduce the risk of identification where information relates to individual research studies, rare conditions, and small recruitment numbers at a single Trust site, particularly when combined with other publicly available trial information.

4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer.

IRAS Number	Project phase	Project site date open to recruitment	Project site actual recruitment end date	Recruited (total)
166544	Not Applicable		31/03/2019	#
303307	Not Applicable	16/11/2023		11
320489	Not Applicable	20/10/2023		0
307898	Not Applicable	15/03/2022	15/07/2022	#
47886	Not Applicable		04/10/2016	0
76092	Phase III	08/02/2013	14/03/2016	0
206347	Phase III		18/04/2016	0
69877	Phase II/III		20/06/2012	0
248335	Phase III			0
31541	Phase III	21/01/2011	18/04/2016	0
17211	Phase III	26/01/2011	29/02/2016	0
123194	Phase III		18/04/2016	0
133883	Phase III		18/04/2016	0
154468	Phase III	30/09/2016	19/03/2020	13
126738	Phase III	24/10/2014	31/10/2023	10
1008479	Phase III			0
265114	Phase II/III	18/04/2024		5
61884	Phase III	15/03/2012	18/04/2016	0
194229	Not Applicable	12/09/2017	28/06/2022	19

In line with the Trust's disclosure control policy, numbers fewer than five have been replaced with "#". This is to reduce the risk of identification where information relates to individual research studies, rare conditions, and small recruitment numbers at a single Trust site, particularly when combined with other publicly available trial information.

- The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials.

1 dedicated research nurse since 2022

- If available, annual counts of invitations/offers made to eligible patients to consider trial participation.

PROPEL – 1 in 2023 and 1 in 2025

Other study data is not available on our research study database or is archived.

Our Ref: 12  
January 2026

If you are not satisfied with the handling of your request, you have the right to request an internal review. Requests for an internal review should be submitted within 40 working days from the date of this response, and should be addressed to [d.wraith@nhs.net](mailto:d.wraith@nhs.net).

If you remain dissatisfied after the internal review, you have the right to appeal to the Information Commissioner's Office (ICO). The ICO can be contacted at:

Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
Website: <https://ico.org.uk/make-a-complaint/>

Our Ref: 12  
January 2026